Chronic graft loss: Immunological and non-immunological factors

Contributions to Nephrology

Volumn 146, Issue , 2005, Pages 54-64

  Hernandez Fuentes, Maria P ^a   Lechler, Robert I ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ACUTE DISEASE; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

ACUTE DISEASE; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; RISK ASSESSMENT; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 16544373760     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (62)

1. Collaborative-Transplant-Study-Group: CTS-K-15103E-Feb2004. 2004. http://www.ctstransplant.org/public/literature.html
2. Libby P, Pober JS: Chronic rejection. Immunity 2001;14:387-397.
3. Gourishankar S, Halloran PF: Late deterioration of organ transplants: A problem in injury and homeostasis. Curr Opin Immunol 2002;14:576-583.
4. Colvin RB: Chronic allograft nephropathy. N Engl J Med 2003;349:2288-2290.
5. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y, et al: The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-723.
6. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-2333.
7. Lombardi G, Barber L, Sidhu S, Batchelor JR, Lechler RI: The specificity of alloreactive T cells is determined by MHC polymorphisms which contact the T cell receptor and which influence peptide binding. Int Immunol 1991;3:769-775.
8. Hernandez-Fuentes MP, Baker RJ, Lechler RI: The alloresponse. Rev Immunogenet 1999;1:282-296.
9. Lechler RJ, Batchelor JR: Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982;155:31-41.
10. Vella JP, Spadafora FM, Murphy B, Alexander SI, Harmon W, Carpenter CB, Sayegh MH: Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997;64:795-800.
11. SivaSai KS, Smith MA, Poindexter NJ, Sundaresan SR, Trulock EP, Lynch JP, Cooper JD, Patterson GA, Mohanakumar T: Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999;67:1094-1098.
12. Hornick PI, Mason PD, Baker RJ, Hernandez-Fuentes M, Frasca L, Lombardi G, Taylor K, Weng L, Rose ML, Yacoub MH, Batchelor R, Lechler RI: Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000;101:2405-2410.
13. Steele DJ, Laufer TM, Smiley ST, Ando Y, Grusby MJ, Glimcher LH, Auchincloss H: Two levels of help for B cell alloantibody production. J Exp Med 1996;183:699-703.
14. Mason PD, Robinson CM, Lechler RI: Detection of donor-specific hyporesponsiveness following late failure of human renal allografts. Kidney Int 1996;50:1019-1025.
15. Hornick PI, Mason PD, Yacoub MH, Rose ML, Batchelor R, Lechler RI: Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998;97:1257-1263.
16. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Lechler RI: The role of the allograft in the induction of donor-specific T cell hyporesponsiveness. Transplantation 2001;72:480-485.
17. Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, Mancini D, Rose EA, Cortesini R, Michler RE, Suciu Foca N: Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996;98:1150-1157.
18. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI: Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001;167:7199-7206.
19. Parker W, Bruno D, Holzknecht ZE, Platt JL: Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994;153:3791-3803.
20. Scornik JC, Salomon DR, Howard RJ, Pfaff WW: Evaluation of antibody synthesis in broadly sensitized patients. Transplantation 1988;45:95-100.
21. Ibrahim S, Dawson DV, Sanfilippo F: Predominant infiltration of rejecting human renal allografts with T cells expressing CD8 and CD45RO. Transplantation 1995;59:724-728.
22. Hayry P, Defendi U: Mixed lymphocyte culture produce effector cells: In vitro model for allograft rejection. Science 1970;168:133-135.
23. Ouwehand AJ, Baan CC, Roelen DL, Vaessen LM, Balk AH, Jutte NH, Bos E, Claas FH, Weimar W: The detection of cytotoxic T cells with high-affinity receptors for donor antigens in the transplanted heart as a prognostic factor for graft rejection. Transplantation 1993;56:1223-1229.
24. Mestre M, Massip E, Bas J, Alsina J, Romeu A, Castelao AM, Buendia E, Grinyo JM: Longitudinal study of the frequency of cytotoxic T cell precursors in kidney allograft recipients. Clin Exp Immunol 1996;104:108-114.
25. Vasconcellos LM, Asher F, Schachter D, Zheng XX, Vasconcellos LH, Shapiro M, Harmon WE, Strom TB: Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998;66:562-566.
26. Sharma VK, Bologa RM, Li B, Xu GP, Lagman M, Hiscock W, Mouradian J, Wang J, Serur D, Rao VK, Suthanthiran M: Molecular executors of cell death - Differential intrarenal expression of Fas ligand, Fas, granzyme B, and perform during acute and/or chronic rejection of human renal allografts. Transplantation 1996;62:1860-1866.
27. Wever PC, Boonstra JG, Laterveer JC, Hack CE, van der Woude FJ, Daha MR, ten Berge IJ: Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 1998;66:259-264.
28. Krieger NR, Yin DP, Garrison Fathman C: CD4+ but not CD8+ cells are essential for allorejection. J Exp Med 1996;184:2013-2018.
29. Krieger NR, Ito H, Fathman CG: Rat pancreatic islet and skin xenograft survival in CD4 and CD8 knockout mice. J Autoimmun 1997;10:309-315.
30. Grimm PC, Nickerson P, Gough J, McKenna R, Jeffery J, Birk P, Rush DN: Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant 1999;3:257-270.
31. Sijpkens YW, Joosten SA, Wong MC, Dekker FW, Benediktsson H, Bajema IM, Bruijn JA, Paul LC: Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004;65:2409-2418.
32. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria - An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-714.
33. Russell PS, Chase CM, Winn HJ, Colvin RB: Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994;152:5135-5141.
34. Suciu Foca N, Reed E, Marboe C, Harris P, Yu PX, Sun YK, Ho E, Rose E, Reemtsma K, King DW: The role of anti-HLA antibodies in heart transplantation. Transplantation 1991;51:716-724.
35. Sundaresan S, Mohanakumar T, Smith MA, Trulock EP, Lynch J, Phelan D, Cooper JD, Patterson GA: HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998;65:648-653.
36. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM: Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000;343:1078-1084.
37. Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J: HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999;1:334-342.
38. Collaborative Transplant Study Group: First cadaver kidney transplants 1985-2002, HLA-+A+B+DR mismatches. 2004. http://www.ctstransplant.org/public/ data/hrml_all/CTS-K-21103-Feb2004.html
39. Cecka M: Clinical outcome of renal transplantation. Factors influencing patient and graft survival. Surg Clin North Am 1998;78:133-148.
40. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752-756.
41. Tesi RJ, Elkhammas EA, Henry ML, Davies EA, Salazar A, Ferguson RM: Acute rejection episodes: Best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc 1993;25:901-902.
42. Matas AJ: Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients. Pediatr Transplant 2000;4:92-99.
43. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I, Hataya H, Ikeda M, Honda M, Hasegawa A: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003;14:1046-1052.
44. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH: Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996;93:12439-12444.
45. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H Jr: Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001;167:5522-5526.
46. Pelletier RP, Hennessy PK, Adams PW, VanBuskirk AM, Ferguson RM, Orosz CG: Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002;2:134-141.
47. Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF: The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev 2003;196:197-218.
48. van Kampen CA, Roelen DL, Versteeg-van der Voort Maarschalk MF, Hoitsma AJ, Allebes WA, Claas FH: Activated HLA class I-reactive cytotoxic T lymphocytes associated with a positive historical crossmatch predict early graft failure. Transplantation 2002;74:1114-1119.
49. Wu GD, Jin YS, Salazar R, Dai WD, Barteneva N, Barr ML, Barsky LW, Starnes VA, Cramer DV: Vascular endothelial cell apoptosis induced by anti-donor non-MHC antibodies: A possible injury pathway contributing to chronic allograft rejection. J Heart Lung Transplant 2002;21:1174-1187.
50. Magro CM, Klinger DM, Adams PW, Orosz CG, Pope-Harman AL, Waldman WJ, Knight D, Ross P Jr: Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant 2003;3:1264-1272.
51. Opelz G: Factors influencing long-term graft loss. The Collaborative Transplant Study. Transplant Proc 2000;32:647-649.
52. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
53. Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
54. Lin CY, Graca L, Cobbold SP, Waldmann H: Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol 2002;3:1208-1213.
55. van Maurik A, Herber M, Wood KJ, Jones ND: Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: Implications for anti-CD154 immunotherapy. J Immunol 2002;169:5401-5404.
56. Camara NO, Sebille F, Lechler RI: Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 2003;33:3473-3483.
57. Hall BM, Pearce NW, Gurley KE, Dorsch SE: Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990;171:141-157.
58. Kingsley CI, Karim M, Bushell AR, Wood KJ: CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002;168:1080-1086.
59. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001;166:3789-3796.
60. Salama AD, Najafian N, Clarkson MR, Harmon WE, Sayegh MH: Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 2003;14:1643-1651.
61. Game DS, Hernandez-Fuentes MP, Lechler RI: Everollmus and Basiliximab permit suppression by human CD4+CD25+ cell in vitro. Am J Transplant 2004; in press.
62. Jiang S, Camara N, Lombardi G, Lechler RI: Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003;102:2180-2186. Epub 2003 May 29.